[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Animuscure Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100598492","phase-2-a-study-of-amc6156-in-people-with-sarcopenia-100598492",false,"NCT07072195","A Study of AMC6156 in People With Sarcopenia","A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of AMC6156 in Patients With Sarcopenia","Inclusion Criteria:\n\n* Voluntary participation with written informed consent\n* Male ≥ 65 years or postmenopausal female\n* Diagnosed with sarcopenia:\n* ASM \\\u003C 7.0 kg\u002Fm² (men) or \\\u003C 5.4 kg\u002Fm² (women)\n* Plus low handgrip strength or SPPB ≤ 9\n* MNA screening score ≥ 8\n* Body weight ≥ 35 kg, BMI between 15-30 kg\u002Fm²\n* Willing and able to follow exercise and nutrition guidance\n\nExclusion Criteria:\n\n* Allergy to investigational drug\n* History of GI bleeding, ulcers, or severe liver\u002Fkidney\u002Fheart disease\n* QTc ≥ 450 ms with symptoms\n* Severe COPD, uncontrolled diabetes or thyroid disease\n* Diseases causing cachexia or muscle wasting (e.g., ALS, Parkinson's)\n* Vitamin D deficiency (\\\u003C10 ng\u002FmL), hemoglobin \\\u003C10 g\u002FdL\n* Severe psychiatric disorders or MMSE \\\u003C 21\n* Inability to walk or recent fracture\u002Fsurgery affecting mobility\n* Use of prohibited medications or recent participation in other clinical trials\n* Investigator deems the subject unsuitable for the study","ALL","65 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This clinical trial aims to find out whether AMC6156 can improve physical function and is safe in older adults with sarcopenia. Participants will take AMC6156 or a placebo daily for 12 weeks, and their movement, strength, and safety will be regularly monitored through tests and checkups.",[26,27],"Sarcopenia in Elderly","Sarcopenia",[29],"sarcopenia","RECRUITING","2025-07-24",{"date":33,"type":34},"2025-07-29","ACTUAL",{"date":36,"type":34},"2025-07-01",{"date":38,"type":20},"2026-06",{"name":40,"class":41},"Animuscure Inc.","INDUSTRY",4,""]